++
Disease syndrome:
Gilbert syndrome (GS) is a hereditary defect in bilirubin metabolism.
It has a prevalence of 3% to 7% in the United States of America, but worldwide this varies immensely with levels approaching 10% in parts of Western Europe.
A 60% to 70% reduction in the liver’s ability to conjugate bilirubin leads to unconjugated (indirect) hyperbilirubinemia which may intermittently manifest as clinical jaundice.
Jaundice due to GS does not indicate or result in liver damage.
GS itself has no long-term harmful effects and does not reduce life expectancy.
Hereditary basis:
Differential diagnosis:
Other genetic defects of bilirubin metabolism (Table 74-1)
Other causes of unconjugated hyperbilirubinemia such as hemolysis, drugs, and thyrotoxicosis
GS and Pharmacogenetics:
Any drug which is metabolised via glucuronidation may have altered activity in patients with GS.
There is associated drug toxicity in GS with the chemotherapeutic agent, irinotecan. It is associated with an increased risk of neutropenia and diarrhoea.
++
+++
Diagnostic Criteria and Clinical Characteristics
++
GS can be confidently diagnosed with a thorough clinical history, examination, and routine biochemistry (Table 74-2 below).
++